What’s the current market cap for Cullinan Therapeutics stock?

Cullinan Therapeutics (CGEM) has a market cap of $830m as of June 07, 2026.

What is the P/E ratio for Cullinan Therapeutics stock?

The price to earnings (P/E) ratio for Cullinan Therapeutics (CGEM) stock is 0 as of June 07, 2026.

Does Cullinan Therapeutics stock pay dividends?

No, Cullinan Therapeutics (CGEM) stock does not pay dividends to its shareholders as of June 07, 2026.

When is the next Cullinan Therapeutics dividend payment date?

Cullinan Therapeutics (CGEM) stock does not pay dividends to its shareholders.

What is the beta indicator for Cullinan Therapeutics?

Cullinan Therapeutics (CGEM) has a beta rating of -0.09. This means that it has an inverse relation to market volatility.

Buy Cullinan Therapeutics stock | $CGEM Share Price

13:30

15:10

16:45

18:25

20:00

About Cullinan Therapeutics

Cullinan Therapeutics Inc is a clinical-stage biopharmaceutical company developing therapies for autoimmune diseases and cancer. Its development pipeline comprises the following drug candidates: CLN-978, a CD19xCD3 bispecific T cell engager that is being developed for autoimmune diseases; CLN-049, a FLT3xCD3 bispecific T cell engager being evaluated in an ongoing clinical trial in patients with relapsed/refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS); Velinotamig, a BCMAxCD3 bispecific T cell engager being developed to counter autoimmune diseases; and Zipalertinib, being developed as a treatment for non-small cell lung cancer. Additionally, the company is developing several preclinical programs in autoimmune diseases and oncology.

Ticker

$CGEM

Sector

Health

Primary listing

NASDAQ

Employees

109

Headquarters

Cambridge, United States

Website

cullinantherapeutics.com

CGEM Metrics

BasicAdvanced

$830m

-$3.72

-0.09

What the Analysts think about CGEM

Analyst ratings (Buy, Hold, Sell) for Cullinan Therapeutics stock.

Bulls say / Bears say

As of December 31, 2025, Cullinan held $439.0 million in cash, cash equivalents, investments and interest receivable, providing runway into 2029 under its current operating plan. (GlobeNewswire)

On May 19, 2026, the FDA granted Orphan Drug Designation to CLN-049 for relapsed/refractory AML, qualifying the asset for incentives including seven years of U.S. market exclusivity upon approval. (GlobeNewswire)

The U.S. FDA accepted the New Drug Application for zipalertinib in EGFR exon 20 insertion NSCLC, advancing the program toward a PDUFA target action date of February 27, 2027. (RTTNews)

Cullinan reported a full‐year net loss of $219.9 million for 2025, up from $167.4 million in 2024, and increased R&D expenses of $187.4 million (a >30% rise year-over-year), reflecting high cash burn absent commercial revenues. (GlobeNewswire)

Cullinan discontinued two pipeline programs, CLN-619 and CLN-617, following clinical data reviews, underscoring execution risk in its early-stage portfolio. (Reuters)

In November 2025, officer Jennifer Michaelson sold 4,000 shares, which may signal tempered insider confidence despite the company’s clinical progress. (Reuters)

Data summarised monthly by Lightyear AI. Last updated on 3 Jun 2026.

CGEM Financial Performance

Revenues and expenses

QuarterlyAnnual

Q3 24

QoQ growth

Revenue

$37bn

-39.75%

Net income

$45bn

107.52%

Profit margin

37.65%

6.78%

CGEM Earnings Performance

Company profitability

QuarterlyAnnual

Q4 23

Q1 24

Q2 24

Q3 24

Q4 24

Actual

$3.69

$2.85

$2.45

$2.42

Expected

$3.55

$2.61

$2.05

$2.31

$3.94

Surprise

3.94%

9.20%

19.51%

4.63%

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.

Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $CGEM

Capital at risk

Market closed

Upcoming events

No upcoming events